SPRY — ARS Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1671858 ·
Last close
$3.65
Market Cap
$366.93M
52W High
$13.15
52W Low
$2.44
ADV30
2,116,931
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 37,710,000 | 27,612,000 | -34,171,000 | -35,587,000 | 251,484,000 | 25,621,000 | 263,439,000 |
| Jun 2026 | 33,658,000 | 20,812,000 | -61,465,000 | -62,339,000 | 249,495,000 | 8,163,000 | 236,983,000 |
| Mar 2026 | 22,681,000 | 16,395,000 | -60,145,000 | -60,618,000 | 287,571,000 | 24,321,000 | 226,263,000 |
| Dec 2025 | 28,087,000 | 21,933,000 | -41,465,000 | -41,324,000 | 327,652,000 | 41,317,000 | 213,394,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-196,405,000
Investing CF
$48,496,000
Financing CF
$104,532,000
CapEx
$-339,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.22
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-417,560,000
Inventory
$11,689,000
Receivables
$46,839,000
ST Investments
$135,682,000
EBIT TTM
$-202,025,000
Pretax Income TTM
$-215,512,000
Interest Exp TTM
$4,920,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$122,136,000
EBITDA
$-195,600,992
Free Cash Flow
$-113,209,128
Enterprise Value
$339,135,232
Total Cash
$138,354,000
Total Debt
$197,015,008
Shares Out
100,528,400
Trailing EPS
$-2.01
Book Value
$-0.12
ROE
-294.6%
ROA
-39.5%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 84,278,000 | -179,448,000 | -171,298,000 | 327,652,000 | 213,394,000 | 114,258,000 | -170,866,000 |
| Dec 2024 | 89,149,000 | -3,083,000 | 7,998,000 | 351,153,000 | 94,355,000 | 256,798,000 | 13,548,000 |
| Dec 2023 | 30,000 | -67,520,000 | -54,365,000 | 233,188,000 | 2,428,000 | 230,760,000 | -59,266,000 |
| Dec 2022 | 1,316,000 | -35,516,000 | -34,682,000 | 281,435,000 | 8,549,000 | 272,886,000 | -40,078,000 |
TTM Snapshot
Revenues TTM
$116,927,000
NetIncome TTM
$-215,432,000
OpCashFlow TTM
—
Assets (Latest)
$249,495,000
Forward EPS
$-0.90
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $3.69 · call volume: 32 · put volume: 2
Expected Move to 2026-12-18:
±$1.43
(38.62%) —
implied range
$2.27 –
$5.12
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CYDY | CytoDyn Inc. | $366.64M | $0.25 | — |
| PEPG | PepGen Inc. | $365.73M | $3.88 | — |
| PBYI | PUMA BIOTECHNOLOGY, INC. | $369.13M | $7.14 | — |
| NIKA | NIKA PHARMACEUTICALS, INC | $369.14M | $0.35 | — |
| CRMD | CorMedix Inc. | $371.44M | $4.67 | — |
News headlines (Yahoo Finance, 1h cache)
ARS Pharmaceuticals Inc (SPRY) Q3 2026 Earnings Call Highlights: neffy Market Share Tops 5% as ...
2026-11-06 11:16 · Yahoo
ARS Pharmaceuticals Q3 Earnings Call Highlights
2026-11-06 04:14 · Yahoo
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Lags Revenue Estimates
2026-11-05 21:45 · Yahoo
ARS Pharma Reports Business Highlights and Third Quarter 2026 Financial Results
2026-11-05 21:01 · Yahoo
ARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
2026-10-29 13:00 · Yahoo
ARS Pharma to Report Third Quarter 2026 Financial Results
2026-10-28 20:01 · Yahoo
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-09-01 20:01 · Yahoo
Can ARS Pharmaceuticals, Inc. (SPRY) Climb 297.02% to Reach the Level Wall Street Analysts Expect?
2026-08-20 13:55 · Yahoo
ARS Pharmaceuticals Q2 Earnings Call Highlights
2026-08-14 03:04 · Yahoo
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue Estimates
2026-08-13 21:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.